In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo acquires US rights to generic Xyzal

This article was originally published in Scrip

Executive Summary

Perrigo has bought the US rights to market a generic version of UCB's Xyzal from Synthon Pharmaceuticals for an undisclosed amount. Perrigo now has exclusive US rights to levocetirizine tablets from Synthon, despite ongoing litigation between Synthon and UCB. The firms are engaged in a paragraph IV/Hatch-Waxman litigation over an ANDA filing by Synthon. In April, Synthon filed a US ANDA for generic Xyzal and expects 180 days of marketing exclusivity as it believes it is the first filer of the generic (Scrip Online, April 16th, 2008).

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel